Background and aims Migraine is a common cause of headache among late childhood and adolescence and is the most common cause of severe, recurrent headaches up in 15–19 ys, with a great impairment on quality of life, sociality and school performances. In 2004, Italian Health Ministry rules triptans use in adolescent age. Aims study is assessing safety and effectiveness of Sumatriptan nasal spray in Migraine with Aura adolescent. Methods According to IHS 2004 criteria, 24 migraine with Aura (MA) patients (M/F 13/11) aged 12–17 ys (mean 13.4 SD±1.48), were selected in Headache Centre of Child and Adolescents Neuropsychiatry Department in Naples, between February 2003 and September 2004. Monthly frequency migraine attacks were 3 to 7. All patients were non responders at analgesics and NSAIDs. Standard neurological and clinical laboratory tests, EEG wake and sleep recordings, electrocardiograms, and nasal examinations were performed at first clinic visit. Patients presented visual aura in 42.85%, limbs parestesia 28.57%, and arms hyposthenia 28.57%. Before and after treatment of each migraine, patients scored pain on a four-point scale (0=none; 1=mild; 2=moderate; 3=severe). Results The success of individual Sumatriptan clinical administration appears related to time to treatment, with resolution pain time in 10 minutes for 64.58% and in 30 minutes for 35.42%. Overall, triptan tolerability in adolescents is similar to that reported in adults. The most common specific drug-related adverse event was unpleasant taste, which was reported in 37.58% of patients and epistaxis in 12.52%. Mean scored value pain after treatment with Sumatriptan was 0.75 (SD±0.8) vs 2.89 (SD±1.24) (p=0.000). Conclusions Triptans (selective 5-hydroxytryptamine1B/1D serotonin agonists) are a new class of agents used in the treatment of migraine. Study results suggest that Sumatripatn nasal spray may effectively alleviate migraine in adolescents MA patients.

Sumatriptan nasal spray safety and effectiveness in migraine with aura adolescents

CAROTENUTO, Marco;
2006

Abstract

Background and aims Migraine is a common cause of headache among late childhood and adolescence and is the most common cause of severe, recurrent headaches up in 15–19 ys, with a great impairment on quality of life, sociality and school performances. In 2004, Italian Health Ministry rules triptans use in adolescent age. Aims study is assessing safety and effectiveness of Sumatriptan nasal spray in Migraine with Aura adolescent. Methods According to IHS 2004 criteria, 24 migraine with Aura (MA) patients (M/F 13/11) aged 12–17 ys (mean 13.4 SD±1.48), were selected in Headache Centre of Child and Adolescents Neuropsychiatry Department in Naples, between February 2003 and September 2004. Monthly frequency migraine attacks were 3 to 7. All patients were non responders at analgesics and NSAIDs. Standard neurological and clinical laboratory tests, EEG wake and sleep recordings, electrocardiograms, and nasal examinations were performed at first clinic visit. Patients presented visual aura in 42.85%, limbs parestesia 28.57%, and arms hyposthenia 28.57%. Before and after treatment of each migraine, patients scored pain on a four-point scale (0=none; 1=mild; 2=moderate; 3=severe). Results The success of individual Sumatriptan clinical administration appears related to time to treatment, with resolution pain time in 10 minutes for 64.58% and in 30 minutes for 35.42%. Overall, triptan tolerability in adolescents is similar to that reported in adults. The most common specific drug-related adverse event was unpleasant taste, which was reported in 37.58% of patients and epistaxis in 12.52%. Mean scored value pain after treatment with Sumatriptan was 0.75 (SD±0.8) vs 2.89 (SD±1.24) (p=0.000). Conclusions Triptans (selective 5-hydroxytryptamine1B/1D serotonin agonists) are a new class of agents used in the treatment of migraine. Study results suggest that Sumatripatn nasal spray may effectively alleviate migraine in adolescents MA patients.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11591/225154
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact